Liberum Capital reissued their buy rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Monday morning. They currently have a GBX 4,200 ($55.24) target price on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the stock. Barclays PLC restated an equal weight rating and set a GBX 4,000 ($52.61) target price on shares of Shire PLC in a report on Monday, October 30th. Shore Capital restated a buy rating on shares of Shire PLC in a report on Thursday, October 26th. Goldman Sachs Group, Inc. (The) restated a conviction-buy rating on shares of Shire PLC in a report on Tuesday, October 17th. Morgan Stanley dropped their target price on shares of Shire PLC from GBX 5,800 ($76.29) to GBX 5,700 ($74.97) and set an overweight rating on the stock in a report on Thursday, October 12th. Finally, Deutsche Bank AG restated a buy rating and set a GBX 6,000 ($78.92) target price on shares of Shire PLC in a report on Friday, August 4th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Shire PLC has an average rating of Buy and an average target price of GBX 5,272.22 ($69.34).

Shares of Shire PLC (SHP) opened at GBX 3,764.04 ($49.51) on Monday. Shire PLC has a fifty-two week low of GBX 3,435.50 ($45.19) and a fifty-two week high of GBX 5,067 ($66.64).

ILLEGAL ACTIVITY WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at

In other Shire PLC news, insider Anne Minto bought 190 shares of the firm’s stock in a transaction on Friday, September 29th. The stock was acquired at an average price of GBX 3,785 ($49.78) per share, with a total value of £7,191.50 ($9,458.77).

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.